Grand Pharmaceutical publishes 2025 annual report

  • Grand Pharma published its 2025 annual report, highlighting strategic shift toward innovation-led growth and global expansion.
  • Nuclear medicine oncology diagnostics and therapeutics remained key growth driver, supported by continued ramp-up of YiGanTai Yttrium-90 microsphere franchise.
  • YiGanTai secured an additional FDA indication in 2025, positioning it as an FDA-cleared SIRT option for unresectable HCC plus colorectal cancer liver metastases.
  • Group started operations at its Chengdu radiopharmaceutical R&D and manufacturing base in late June 2025, aiming to scale production for pipeline commercialization.
  • Pipeline advanced across radiopharmaceuticals, critical care, ophthalmology, with TLX591-CDx moving toward China filing stage and sepsis drug STC3141 preparing for global Phase III planning.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260429-12135773), on April 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.